MICRORNA EXPRESSION PROFILE IN PLASMA OF PATIENTS WITH CLINICAL FEATURES RELATED TO METABOLIC SYNDROME AND THEIR IMPLICATIONS IN BREAST CANCER.

FARRÉ PL; DUCA RB; PICCIONI F; DALTON GN; LACUNZA E; DIMASE F; BATAGELJ E; DE SIERVI A; DE LUCA P

Congreso; REUNIÓN DE SOCIEDADES DE BIOCIENCIAS 2020; 2020

Metabolic Syndrome (MeS) is a risk factor for breast cancer (BCa).Molecular mechanisms underlaying this association have not been fully elucidated. MiRNAs are small non-coding RNAs that regulate gene expression. Circulating miRNAs can be detected in body fluids. Aberrant expression of miRNAs in both tissues and fluids are linked to several pathologies. Might plasma miRNAome associated to MeS influence BCa development and progression? The aim of this work was to identify the circulating miRNAs in plasma of patients with clinical features linked to MeS and their role in BCa. Healthy women from Hospital Militar Central (CABA) were recruited and divided in two groups, control or MeS-linked disease (MeSL) when presented two or more of these conditions: BMI≥25.00 kg/m2, waist diameter≥82 cm or high blood pressure (systolic≥120, diastolic≥ 80). MiRNAs were isolated from plasma and a pool of each samples were hybridized to GeneChip® miRNA 4.0 Array (Affymetrix). We found 24 miRNAs (FSG1.5 and p value